Difference between revisions of "Part:BBa K3582024"
Sailleshac (Talk | contribs) |
Sailleshac (Talk | contribs) |
||
| Line 4: | Line 4: | ||
The following characteristic properties are observed in this inhibitory peptide sequence: | The following characteristic properties are observed in this inhibitory peptide sequence: | ||
| − | *1] Interaction energy: -11.04 | + | *1] Interaction energy: -11.04 kcal/mol |
| − | *2] Stability value: 6.08285 | + | *2] Stability value: 6.08285 dG units |
*These values are relative to the wild type sequence | *These values are relative to the wild type sequence | ||
This biobrick is able to synthesize the inhibitory peptide which is believed to be able to bind more effectively to PfEMP1 as compared to the wild type sequence. The peptide sequence is designed using saturation mutagenesis. Many residues were mutated and it is thought that this change can confer extra stability to the inhibitory peptide as it binds to the parasite protein. These inhibitors form hydrogen bonds with the PfEMP1 protein to stop PfEMP1’s interaction with ICAM-1. They are rich in Glycine and Proline residues and it has been documented that GP- rich residues bind strongly to the DBL-beta domain of PfEMP1A.[1] | This biobrick is able to synthesize the inhibitory peptide which is believed to be able to bind more effectively to PfEMP1 as compared to the wild type sequence. The peptide sequence is designed using saturation mutagenesis. Many residues were mutated and it is thought that this change can confer extra stability to the inhibitory peptide as it binds to the parasite protein. These inhibitors form hydrogen bonds with the PfEMP1 protein to stop PfEMP1’s interaction with ICAM-1. They are rich in Glycine and Proline residues and it has been documented that GP- rich residues bind strongly to the DBL-beta domain of PfEMP1A.[1] | ||
| Line 18: | Line 18: | ||
<partinfo>BBa_K3582024 SequenceAndFeatures</partinfo> | <partinfo>BBa_K3582024 SequenceAndFeatures</partinfo> | ||
| + | ===References=== | ||
| + | *[1]Structure-Guided Identification of a Family of Dual Receptor-Binding PfEMP1 that Is Associated with Cerebral Malaria. (2017, March 8). PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374107/ | ||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display | ||
Revision as of 18:07, 23 October 2020
Inhibitory Sequence 1 for PfEMP-1 and ICAM-1 interaction
The following characteristic properties are observed in this inhibitory peptide sequence:
- 1] Interaction energy: -11.04 kcal/mol
- 2] Stability value: 6.08285 dG units
- These values are relative to the wild type sequence
This biobrick is able to synthesize the inhibitory peptide which is believed to be able to bind more effectively to PfEMP1 as compared to the wild type sequence. The peptide sequence is designed using saturation mutagenesis. Many residues were mutated and it is thought that this change can confer extra stability to the inhibitory peptide as it binds to the parasite protein. These inhibitors form hydrogen bonds with the PfEMP1 protein to stop PfEMP1’s interaction with ICAM-1. They are rich in Glycine and Proline residues and it has been documented that GP- rich residues bind strongly to the DBL-beta domain of PfEMP1A.[1]
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
- [1]Structure-Guided Identification of a Family of Dual Receptor-Binding PfEMP1 that Is Associated with Cerebral Malaria. (2017, March 8). PubMed Central (PMC). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374107/